HP515
Phase 2Small molecule
HP515 is one of 45 small molecule programs targeting Alcoholic Fatty Liver Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Actos
TakedaPhase 3
Rezdiffra
Madrigal PharmaceuticalsPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Farxiga
AstraZenecaPhase 2
Ozempic
Novo NordiskPhase 2
Bayer Aspirin
BayerPhase 2
Lipaglyn
ZZydus Therapeutics Inc.
Phase 2
Combination Drug
BayerPhase 3
Efruxifermin
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HP515. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHinova Pharmaceuticals Inc.